Bhaskar Narayana

Hyderabad-based Natco Pharma Limited, on December 21, received the approval from Food & Drug Administration (FDA) for marketing the prescription version of Lanzoprazole, CFO of the company Bhaskar Narayana told CNBC-TV18 in an interview.

Will maintain API growth inline with Q2FY13: Natco Pharma

Natco Pharma yesterday received US Food and Drug Administration's approval for its anti-ulcer drug Lansoprazole and the stock saw a 6 percent surge to a high life of Rs 498.90. The drug is a generic version of Prevacid marketed by Takeda Pharmaceuticals.

Won license to make one of Bayers product: Natco's CFO

In an interview with CNBC-TV18, Bhaskar Narayana, finance director & CFO of Natco Pharma spoke about the judgment where the company is granted compulsory license to manufacture one of the Bayer’s products. He also talks about the market size of the drug and the amount of royalty to be paid.

See good boost in revenues in FY13: Natco Pharma

In an interview to CNBC-TV18, Bhaskar Narayana, chief financial officer of Natco Pharma says, FY13 should see atleast one abbreviated new drug application (ANDA) coming through. “FY13 would be a very exciting year for the company because it should result in good boost to the revenues,” he adds.

QIP of Rs 100cr to result in 7-8% dilution: Natco Pharma

Some agencies have been reporting that Natco Pharma’s fund raising plan might be expedited and take place in the next one or two months. Finance director and chief financial officer Bhaskar Narayana told CNBC-TV18 that the Rs 100 crore qualified institutional placement (QIP) would result in 7-8% dilution.

Will make, sell products in bio-generic space: Natco Pharma

In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO of Natco Pharma talks about the pact with the Swiss based company and its impact on the company’s revenues going forward.

Natco Pharma to sell US pharma biz when opportunity knocks

Bhaskar Narayana, Finance Director & CFO, Natco Pharma said that he no longer sees synergies with SaveMart Pharmacy existing. The revenue being generated from SaveMart Pharmacy is USD 18 million.

Natco Pharma may sell US-based pharmacy store SaveMart

In an interview on CNBC-TV18, Bhaskar Narayana, finance director and chief financial officer at Natco Pharma said that synergies with the SaveMart Pharmacy exist no longer.

Natco Pharma eyes 9-10% revenue growth in FY11

In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director and CFO, Natco Pharma, speaks about the results and gives his outlook going forward.

At-risk launch likely for Tamiflu generic: Natco Pharma

In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma gave his perspective on the tie-up with Alvogen and the first-to-file opportunity for Tamiflu.

Expect to cross Rs 500cr in revenue this yr: Natco Pharma

Hyderabad-based Natco Pharma has sought permission from drug major Pfizer to sell discounted copies of its HIV drug. In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma threw light on the development and spoke on the company's business plans going forward.